QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 限定条件 专题：中南大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文 JAMA Oncology, 2018, 卷号: 4, 期号: 11, 页码: 1569-1575 作者:  Han, Baohui*;  Li, Kai*;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：7/0  |  提交时间：2019/12/03 anlotinib  non-small-cell lung carcinoma   Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302) 期刊论文 British Journal of Cancer, 2018, 卷号: 118, 期号: 5, 页码: 654-661 作者:  Han, Baohui*;  Li, Kai;  Zhao, Yizhuo;  Li, Baolan;  Cheng, Ying 收藏  |  浏览/下载：9/0  |  提交时间：2019/12/03 non-small-cell lung cancer  multitarget  tyrosine kinase inhibitor  anlotinib  third line   A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer 期刊论文 Journal of Thoracic Oncology, 2015, 卷号: 10, 期号: 1, 页码: 206-211 作者:  Lu, Shun*;  Li, Lu;  Luo, Yi;  Zhang, Li;  Wu, Gang 收藏  |  浏览/下载：8/0  |  提交时间：2019/12/03 Etoposide  Carboplatin  Rh-endostatin  Extensive-stage small-cell lung cancer  Survival